MedTrace Logo

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

NCT01289132 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 926

Last updated 2011-02-03

No results posted yet for this study

Summary

The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

Placebo

Placebo-matching tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Candesartan cilexetil

Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.

Sponsors & Collaborators

Principal Investigators

  • Professor Geriatric Medicine and Nephrology · Osaka University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-07-31
Completion
2008-07-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289132 on ClinicalTrials.gov